Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficasy and safety of SR25990C(loading dose:300mg, maintenance
dose:75mg/day) in comparison with the standard Japanese treatment(ticlopidine) in patients
with acute coronary syndrome without ST-segment elevation and planned for percutaneous
coronary intervention(including stenting).